Summary: Ardent Health Partners saw its stock plunge after leadership upheaval combined with a mid-quarter warning on patient volumes. The company reported an unplanned CEO exit effective immediately and said it has observed volume softness during the second quarter. Management reaffirmed full-year 2026 adjusted EBITDA guidance that sits below the 2025 adjusted EBITDA figure, and the shares dropped to a new 52-week low amid existing legal pressures and analyst downgrades.
Shares of Ardent Health Partners fell sharply, down 14.4% in morning trading, after the company disclosed a sudden change at the top and signaled weaker volumes across its portfolio for the current quarter. The stock reached a 52-week low of $7.71 before partially recovering to $7.94.
The immediate catalyst was a June 2 press release announcing that Marty Bonick stepped down as President and CEO to "pursue other opportunities," and that Chief Operating Officer Dave Caspers would assume the CEO role immediately. Adding to investor concern, Chief Financial Officer Alfred Lumsdaine said, "During the second quarter, we’ve observed volume softness across our portfolio," and noted that the company had accelerated its IMPACT operational program in response.
While Ardent reaffirmed full-year 2026 adjusted EBITDA guidance in a range of $485–$535 million, that midpoint and range remain below the $545 million of adjusted EBITDA the company reported in 2025. That year-over-year decline in adjusted EBITDA contributed to investor unease and weighed on the share price.
Market sentiment was already strained for Ardent. Multiple securities class action lawsuits alleging misstatements related to accounts receivable and malpractice insurance reserves have applied pressure on the stock for months. In addition, four analysts had already trimmed earnings estimates ahead of the latest developments.
The broader U.S. equity market provided little support as the selloff unfolded, with the S&P 500 down 0.4%, the Dow Jones Industrial Average declining 0.8%, and the NASDAQ easing 0.5% during the same session. Together, the unplanned management change, the intra-quarter volume softness, the reaffirmed but lower-than-last-year EBITDA guidance, and a weak broader market combined to push ARDT shares to their lowest level in more than a year.
Contextual note: The company stated it has accelerated its IMPACT operational program in direct response to the observed volume softness. The reaffirmed 2026 guidance and the company’s comments were part of the June 2 announcement that also detailed the leadership transition.